Auto-immune

Delve into the world of Auto-immune in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Auto-immune to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs
CompanyDeals

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

InnoCare Pharma Limited (HKG: 9969; SHA: 688428) announced that it has entered into a strategic research, development, and licensing agreement with Eli Lilly and Company (NYSE: LLY) to develop innovative…

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Drug

Eli Lilly’s Taltz Wins Second NMPA Approval for Ankylosing Spondylitis

CompanyDrug

MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study

CompanyDrug

Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study

CompanyDrug

Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis

CompanyDrug

GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis

CompanyDrug

Zelgen’s Jakitinib Phase III Study Meets Primary Endpoint for Myelofibrosis

CompanyDeals

China NT Pharma Group Inks Licensing Deal for Orticumab in Asia

Drug

Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA

Show More